Marshall Wace, LLP Nuvectis Pharma, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 42,814 shares of NVCT stock, worth $217,066. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,814
Previous 33,868
26.41%
Holding current value
$217,066
Previous $214,000
25.7%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.65MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$2.85 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA301KShares$1.53 Million0.0% of portfolio
-
Baldwin Brothers LLC174KShares$882,8390.08% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$422,8980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA79.7KShares$404,1600.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $74.2M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...